Project Grant R43HL180206
Award Date 8/1/25
Completion Date 5/31/26
Dollars Obligated $496K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,102 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Peca Labs Inc. to develop a novel, fully-polymeric, biomimetic prosthetic mitral valve. The objective is to create a valve that combines the positive characteristics of both biological and mechanical mitral valves to improve durability, performance, and patient outcomes. Peca Labs will subject the polymer leaflet material to hydrodynamic...
- The National Heart Lung and Blood Institute (NHLBI), through the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $709,718 Project Grant to Florida International University (FIU) on September 1, 2025. The objective of this award is to develop methods for storing and preserving living valvular allografts (tissue transplants) ex vivo, to maintain their viability and availability for cardiac valve transplantation procedures. The project aims to integrate a preservation solution...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $742,323 to Vanderbilt University to develop a new bioprosthetic aortic valve made from the pulmonary visceral pleura (PVP) tissue. The research aims to demonstrate the PVP valve's superior mechanical durability, calcification resistance, and hemodynamic performance compared to current bioprosthetic valves, in order to improve the long-term durability of...
- The National Heart Lung and Blood Institute (NHLBI), part of the U.S. National Institutes of Health (NIH), awarded a $460,625 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Yale University on August 10, 2025. The objective of this project is to develop highly tunable and customizable Tissue Engineered Vascular Conduits (TEVCs) using a novel bioprinting method that can directly print fully physiological materials, including cell-laden tissues. The project aims...
- The U.S. National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,364,080 project grant to Vesteck, Inc. on September 15, 2025. The grant supports the development and feasibility testing of Vesteck's novel endovascular suturing device for augmenting endograft fixation during endovascular repair of abdominal aortic aneurysms (AAAs). The device aims to reduce reinterventions due to endograft migration or type 1A...
- This $298,368 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a novel device for treating mitral valve regurgitation. The project aims to optimize the device design and procedure through bench testing, followed by acute in vivo studies to demonstrate the feasibility of the approach. The funding recipient, Link Medical LLC, has invented a catheter-based technology intended to restore proper mitral...
- This federal Project Grant award of $1,356,922.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of novel hydrogel-coated electrospun (HES) biomaterials for replacement heart valves. The key objectives are to: Identify optimal biomaterial and leaflet geometry characteristics to develop replacement heart valves with greater durability, resistance to thrombosis, and improved hemodynamics. This will leverage the...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $464,229 to Limax Biosciences Inc. to advance the development of their HEMOMAX biodegradable hydrogel sealant for use in vascular surgery. The key objectives are to: (1) conduct comprehensive bench performance testing, including sterilization validation and endotoxin assessment, and (2) evaluate the safety and efficacy of HEMOMAX in a...
- The National Institutes of Health's National Heart, Lung and Blood Institute awarded Fluidform Inc. a $766,107 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) from April 1, 2021 to March 31, 2022. The grant funds the development of an advanced bioprosthetic collagen heart valve using 3D printing techniques to recreate the collagen fiber architecture and mechanical properties of native heart valve leaflets. Fluidform will collaborate with Carnegie Mellon...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $410,449 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Leland Stanford Junior University (Stanford University) on August 1, 2025. The funding supports research to develop novel synthetic biology strategies that would enable the quantitative and dynamic regulation of growth factors and cytokines produced from human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs). The goal...